Evidence map›Paper›PMID 34644743›Full record

ArticleEinstein (Sao Paulo, Brazil)2021

Olfactory dysfunction in the scenario of COVID-19 pandemic in patients screened by the telemonitoring.

Raíssa Camelo Valletta, Leandro Azevedo de Camargo, Stela Oliveira Rodrigues, Sarah Vidal da Silva, Mateus Capuzzo Gonçalves, Nathálya Rodrigues Queiroz, Arlindo Rodrigues Galvão Filho, Melissa Ameloti Gomes Avelino

Open access · diamondAbstract read
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Raíssa Camelo VallettaUniversidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0003-3062-1986
Leandro Azevedo de CamargoHospital das Clínicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0002-5254-2018
Stela Oliveira RodriguesUniversidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0002-1472-403X
Sarah Vidal da SilvaHospital das Clínicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0002-2186-7370
Mateus Capuzzo GonçalvesHospital das Clínicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0002-5478-9495
Nathálya Rodrigues QueirozHospital das Clínicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0003-4424-7702
Arlindo Rodrigues Galvão FilhoPontifícia Universidade Católica de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0003-2151-8039
Melissa Ameloti Gomes AvelinoUniversidade Federal de Goiás, Goiânia, GO, Brazil.ORCID http://orcid.org/0000-0003-0342-0978
Universidade Federal de Goiás · BRPontifícia Universidade Católica de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the clinical and epidemiological profile of patients with olfactory dysfunction in the scenario of COVID-19 pandemic.

methodsThe study selected patients with loss of smell, previously screened by telemonitoring system of the Municipal Health Department of Goiânia (GO), Brazil, who agreed to answer a questionnaire about COVID-19 symptoms and findings of exams. The interviews were conducted by six otolaryngologists, who applied the specific questionnaire, over the phone.

resultsA total of 13,910 patients underwent telemonitoring, and 627 (4.51%) had olfactory loss complaints. Out of them, 330 were included in the survey. We observed a higher prevalence of altered smell in women (67%), and in patients aged under 50 years (86%). In most cases the manifestations had a sudden onset (70%), and in the first 5 days of illness (80%). The most prevalent associated symptom was a change in taste (89%), and only 2.7% of interviewed patients required hospitalization.

conclusionAnosmia in COVID-19 is more prevalent in females and individuals aged under 50 years. It is a relevant initial symptom predictive of the disease, together with dysgeusia.

Indexed as

COVID-19Olfaction DisordersAgedFemaleHumansPandemicsSARS-CoV-2Smell

Identifiers

PMID34644743
PMCPMC8483635
OpenAlexW3202408892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.